Nasus Pharma Ltd, a clinical-stage pharmaceutical company specializing in innovative intranasal treatments for emergency medical conditions, has entered into comprehensive agreements with Aptar France S.A.S. and AptarGroup, Inc. (together known as Aptar), a global leader in drug delivery systems. The collaboration aims to advance the clinical development and future commercialization of NS002, Nasus Pharma’s intranasal powder epinephrine product candidate.

This strategic partnership enhances NS002’s development and manufacturing roadmap by leveraging Aptar’s end-to-end drug delivery expertise and production infrastructure. Through the collaboration, Nasus Pharma will gain access to Aptar’s commercially proven Unit Dose System technology, providing a validated dosing mechanism and reducing both regulatory and manufacturing risks.

“This collaboration marks a key milestone for Nasus Pharma and our NS002 program,” said Dan Teleman, chief executive officer of Nasus Pharma. “By partnering with Aptar, we can accelerate our path to market using established regulatory, manufacturing, and supply chain frameworks.”

The agreement creates a strong foundation for NS002’s advancement through regulatory submissions with both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), positioning Nasus Pharma for global commercialization.